Meir Medical Center, 59 Tshernichovski st.
Welcome,         Profile    Billing    Logout  
 5 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shitrit, David
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/24
12/24
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Calendar Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in Japan (based on MATINEE trial) for COPD
Active, not recruiting
3
806
Europe, Canada, Japan, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD
Pulmonary Disease, Chronic Obstructive
08/24
08/24
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Recruiting
3
576
Europe, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Nov 2023 - Dec 2023 : Acceptance of regulatory submission in China for chronic rhinosinusitis with nasal polyps
Recruiting
3
1700
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
09/25
09/25
NCT05483907: To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF

Hourglass Jul 2023 - Dec 2023 : Interim data for the treatment of IPF
Checkmark Initiation of trial in idiopathic pulmonary fibrosis
Nov 2022 - Nov 2022: Initiation of trial in idiopathic pulmonary fibrosis
Recruiting
2
120
Europe, US, RoW
BBT-877, Placebo
Bridge Biotherapeutics, Inc.
Idiopathic Pulmonary Fibrosis
11/24
12/24
Williams, Trevor
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/24
12/24
IMPAHCT-FUL, NCT05557942 / 2021-006864-25: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension

Active, not recruiting
3
462
Europe, Canada, US, RoW
AV-101
Aerovate Therapeutics, Aerovate Therapeutics Inc
Pulmonary Arterial Hypertension
12/25
12/25
Manterfield, Christianne
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/24
12/24
Oliveira, Carmen
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/24
12/24
Blanco, Daniela
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Calendar Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF
Terminated
3
372
Europe, US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
09/23
09/23
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/24
12/24
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Calendar Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in Japan (based on MATINEE trial) for COPD
Active, not recruiting
3
806
Europe, Canada, Japan, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD
Pulmonary Disease, Chronic Obstructive
08/24
08/24
Campos, Frederico Thadeu Assis Figueiredo
CAPACITY, NCT04084678: A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH

Terminated
3
10
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Hypertension, Connective Tissue Disease, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease, Pulmonary Arterial Hypertension
04/23
04/23
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/24
12/24
Clippel, Marie De
CAPACITY, NCT04084678: A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH

Terminated
3
10
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Hypertension, Connective Tissue Disease, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease, Pulmonary Arterial Hypertension
04/23
04/23
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/24
12/24
Ravid, Idan
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/24
12/24

Download Options